Tag: Linkers

Based on a recent analysis published earlier this years DataM Intelligence predict that the market size of the for Antibody-drug Conjugates (ADC) valued at around US $11.9 billion in 2024, is projected to surge past US $30.4 billion by 2033, expanding at a robust CAGR of 11.2% (2025–2033).

Peptide-drug conjugates (PDCs) are an emerging class of targeted therapeutics that combine the specificity of peptides with the potent efficacy of cytotoxic drugs. These...

Targets Most targets of ADC have unique requirements, including  homogenous expression of ADC-accessible tumor surface antigens that internalize well and trafficked to lysosomes.  Ideally the...

Advancements in research have shifted the way we think of combating cancer, and traditional treatment options are on the path to being replaced by...

Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics, presented new data utilizing the company's SNAP site-specific ADC linker technology.

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...